Status:
COMPLETED
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Osteoporosis, Postmenopausal
Eligibility:
FEMALE
60-85 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovas...
Eligibility Criteria
Inclusion
- 60-85 years of age
- Female
- At least two years since last menstrual cycle
Exclusion
- Abnormal or unexplained vaginal bleeding.
- Bone disorders, other than osteoporosis or low bone mass
- History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer).
- History of cerebral vascular accidents or venous thromboembolic events
- Medications outlined
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
9369 Patients enrolled
Trial Details
Trial ID
NCT00088010
Start Date
June 1 2004
End Date
November 1 2009
Last Update
June 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Elk Grove, Illinois, United States, 60007